<DOC>
	<DOCNO>NCT02575378</DOCNO>
	<brief_summary>The optimum regimen maintenance treatment first-line chemotherapy patient metastatic colorectal cancer （mCRC） unknown . This study design determine efficacy safety maintenance treatment capecitabine metronomic chemotherapy plus Chinese Traditional Medicine . In Prospective , open-label , randomise control trial , investigator recruit 159 mCRC patient finish 18 24 week first-line chemotherapy disease evaluation SD , PR CR . The patient accept Chinese traditional diagnosis randomise two group , capecitabine metronomic chemotherapy control group metronomic chemotherapy plus Chinese Traditional Medicine experimental group . This treatment regimen continue progression , death , unacceptable adverse event . The primary endpoint progression-free survival ( PFS ) . Secondary endpoint overall survival ( OS ) , quality life ( QOL ) toxic effect .</brief_summary>
	<brief_title>Maintenance Treatment With Capecitabine Metronomic Chemotherapy Chinese Traditional Medicine Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1. unresectable metastatic colorectal cancer pathological confirmation . 2. patient accepted 1824 week firstline chemotherapy disease evaluation SD , PR CR .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Maintenance Treatment</keyword>
	<keyword>Chinese Traditional Medicine</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>